1de Beer EL,Bottone AE, Voest EE. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment. Eur J Parmacol, 2001,415(1):1
2Gharib MI, Burnett AK. Chemotherapy induced cardio toxicity:Current pranctice and prospects of prophylaxis. Eur J Heart Fail,2002,4(3):235
3Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer, 2005, 44(7):600
4Conklin KA. Coenzyme q10 for prevention of anthracyclineinduced cardiotoxicity. Cancer Ther, 2005, 4(2):110
5Richardson DR, Persson L.,Xu X. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol, 2005,9:466
6Allen J, Thomson JDR, Lewis IJ, et al. Mitral regurgitatio after anthracycline treatment for childhood malignancy. Heart, 2001,85:430
7Talenaka K, Kuwada Y, Sonoda M, et al. Anthracycline induced cardiomyopathies evaluated by tissue Doppler tracking system and strain rate imaging. J Cardio, 2001,37(Suppl 1):129
8Suzuki J, Yanagisawa A, Shiqeyama T, et al. Early detection of anthracycline induced cardiotoxicity by radionuclide angiocardiography. Angiology, 1999, 50(1): 37
9Wassmuth R, Lentzsch S,Erdbuegger U,et al. Subclinical cardiotoxic effect of anthracycline as assessment by magnetic resonance imaging. A pilot study. Am Heart J, 2001, 141:1007
10Jones RL, Miles DW. Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity. Lancet Oncol, 2005,6(2):67
